Zurcher Kantonalbank Zurich Cantonalbank Has $3.48 Million Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 67.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,588 shares of the medical research company’s stock after buying an additional 4,256 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Bio-Rad Laboratories were worth $3,478,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Venturi Wealth Management LLC lifted its stake in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares during the period. Gladius Capital Management LP bought a new stake in Bio-Rad Laboratories in the third quarter valued at about $32,000. Asset Planning Inc acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at about $33,000. UMB Bank n.a. boosted its holdings in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after buying an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. acquired a new position in shares of Bio-Rad Laboratories during the 4th quarter worth about $38,000. 65.24% of the stock is owned by institutional investors.

Analyst Ratings Changes

BIO has been the topic of several recent analyst reports. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Royal Bank of Canada reissued an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $255.34 on Friday. The firm has a market cap of $7.15 billion, a P/E ratio of -3.93 and a beta of 0.99. Bio-Rad Laboratories, Inc. has a twelve month low of $244.00 and a twelve month high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The firm’s 50 day moving average price is $311.97 and its two-hundred day moving average price is $328.01.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.